Highest-materiality recent filing
ADMA Q2 2026 net income $37.8M (+11% YoY); ASCENIV revenue $102.9M (+24% YoY)
Total revenue $124.4M (+2% YoY); GAAP net income $37.8M (+11% YoY); GAAP basic EPS $0.17 (+17% YoY).
ADMA Q1 revenue flat at $114.5M, ASCENIV up 28%; withdraws long-term guidance
Revenue $114.5M flat YoY; ASCENIV rev $97.5M (+28%) offset by BIVIGAM -54%.
ADMA Biologics receives FDA approval to expand ASCENIV label to pediatric patients 2 years+
FDA approved label expansion for ASCENIV to include pediatric primary humoral immunodeficiency patients aged 2 years and older.
ADMA Biologics refutes Culper Research short seller allegations; provides inventory & demand data
Demand for ASCENIV growing; end-user demand increased past two years; current days on hand average 90 days as of March 22, 2026.
ADMA Biologics announces $125M accelerated share repurchase as part of $200M 2026 buyback plan
$125M ASR with JPMorgan; initial receipt of ~6.4M shares (~80% of expected) on March 3, 2026 at $15.57 close.
FY2025 total revenue $510.2M (+20% YoY); ASCENIV revenue $363M (+51% YoY). Gross margin 57.4% vs 51.5%.
ADMA prelim FY2025 rev ~$510-511M, raises FY2026 rev/EBITDA guidance, targets >$1.1B by 2029
Preliminary FY2025 total revenue ~$510-511M, meeting or exceeding prior guidance. Cash grew to ~$88M with ~$40M Q4 operating cash flow.
ADMA Q3 revenue $134.2M (+12% YoY); raises FY25 revenue guidance to $510M+, FY26 to $630M+
GAAP net income $36.4M (+1% YoY); adjusted EBITDA $58.7M (+29% YoY).
ADMA Biologics Q2 revenue up 29% underlying; launches yield-enhanced IG mfg
Q2 2025 total revenue $122.0M, up 14% YoY (29% excluding $12.6M prior-year Medicaid reversal).
ADMA Q1 revenue up 40% to $114.8M; raises FY2025/2026 guidance; authorizes $500M buyback
Q1 total revenue $114.8M (+40% YoY); GAAP net income $26.9M (+51% YoY); adjusted EBITDA $47.9M (+81% YoY).
ADMA Biologics receives FDA approval for yield enhancement process; expects ~20% output increase
FDA approved innovative production yield enhancement process increasing yields by ~20% from same plasma volume.
ADMA Biologics FY24 revenue $426.5M (+65% YoY); raises FY25/26 guidance
FY 2024 total revenue $426.5M (+65% YoY); GAAP net income $197.7M incl. $84.3M tax benefit; Adjusted EBITDA $164.6M (+309% YoY).
ADMA prelim FY2024 rev $417-425M, guides FY2025 >$485M
FY2024 preliminary total revenue $417-425M, exceeding prior guidance of $415M; cash >$100M with $30M debt repaid in Q4.
ADMA Biologics Q3 total revenue $119.8M (+78% YoY); GAAP net income $35.9M (+1,300%)
Revenue $119.8M (+78% YoY); GAAP net income $35.9M (+1,300%); Adj. EBITDA $45.4M (+256%)
ADMA Biologics Q2 revenue $107.2M (+78% YoY); raises FY2024 revenue guidance to >$400M
Q2 2024 total revenue $107.2M, up 78% YoY; GAAP net income $32.1M vs loss of $6.4M a year ago.
ADMA Biologics Q1 revenue $81.9M (+44% YoY); raises FY2024-25 guidance
GAAP net income $17.8M vs net loss of $6.8M in prior year; adjusted EBITDA $26.4M, a 970% increase.
FDA approves extended room temperature storage for ADMA's ASCENIV and BIVIGAM
FDA approved supplemental BLAs to allow 4-week room temperature (25°C) storage at any time during the 36-month shelf life.
ADMA Biologics Q4 rev $73.9M (+48%); FY rev $258.2M; raises FY24/25 guidance
Q4 2023 total revenue $73.9M, up 48% YoY; FY 2023 total revenue $258.2M, up 68% YoY.
ADMA Biologics CFO Brian Lenz steps down; CEO Grossman named interim CFO
CFO Brian Lenz transitions to consulting role effective April 1, 2024; consulting agreement through March 31, 2025.
ADMA raises FY2024-25 revenue guidance; preliminary Q4 rev $72-74M, FY rev $256-258M
Q4 2023 preliminary revenue $72-74M; full year $256-258M.
ADMA Biologics refinances with $135M Ares facility, repays $159M Hayfin debt, reduces debt 15%
New $135M senior secured credit facility ($72.5M revolver + $62.5M term loan) fully drawn to repay prior Hayfin debt.
FDA approves ADMA's BIVIGAM for pediatric PI patients aged 2 and older
FDA approved supplemental BLA for BIVIGAM to treat primary humoral immunodeficiency (PI) in patients 2 years and older.
FDA approval for Laurel, MD facility (10th ADMA BioCenters center) to introduce source plasma into interstate commerce.
ADMA Biologics Q3 2023: first-time net income $2.6M, revenue $67.3M (+64% YoY), raises FY guidance
Total revenues $67.3M, up 64% YoY; first-time positive GAAP net income of $2.6M (vs $14.9M loss YoY).
ADMA Biologics raises FY2023 revenue guidance to >$240M; Q2 revenue up 77% to $60.1M
Q2 2023 total revenues $60.1M (+77% YoY); gross margin 27.8% (vs. 22.9% Q2 2022); normalized margin 31-32% excl. IT disruption.
ADMA Biologics receives FDA approval for ninth plasma collection center in Dallas, GA
FDA approved Dallas, GA facility's BLA; center began plasma collection in Q3 2022.
ADMA Biologics Q1 revenue $56.9M (+96% YoY); first-time positive Adjusted EBITDA $2.5M
Total revenues $56.9M, up 96% YoY; net loss narrowed to $6.8M from $25.0M.
On December 30, 2024, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Eduardo Rene Salas to serve on the Board as a Class I director with a term expiring at the Company’s 2026 annual meeting of stockholders.
On November 19, 2024, Bryant E. Fong notified ADMA Biologics, Inc. (the “Company”) that he resigned, effective immediately, as a member of the Company’s Board of Directors (the “Board”) and any committees of the Board in order to devote more time to his roles as Managing Director of Biomark Capital Fund and as Partner and Co-Portfolio Manager of Stonepine Capital Management.
Brad Tade, former Vice President, Financial Operations of ADMA Biologics, Inc. (the "Company"), was promoted to Chief Financial Officer and Treasurer of the Company
Effective April 1, 2024 (the “Effective Date”), Kaitlin Kestenberg, former Senior Vice President, Compliance & Project Operations of ADMA Biologics, Inc. (the “Company”), was promoted to Chief Operating Officer and Senior Vice President, Compliance of the Company
Effective as of April 1, 2024, Brian Lenz, Executive Vice President, Chief Financial Officer & General Manager, ADMA BioCenters, will transition from these positions to a consulting role with the Company (the “CFO Transition”).
On September 28, 2023, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Alison C. Finger to serve on the Board as a Class I director with a term expiring at the Company’s 2026 annual meeting of stockholders.
On October 15, 2021, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Young T. Kwon, Ph.D. to serve on the Board as a Class II director with a term expiring at the Company’s 2024 annual meeting of stockholders.
Max materiality 0.85 · Median 0.62 · Most common event earnings